Tick-borne encephalitis immunoglobulin human solution for injection 5ml vials
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 22 · 1997–2025
Showing the 50 most relevant studies, sorted by most relevant.
E. Pustijanac, M. Buršić, J. Talapko, et al.
Microorganisms, 2023
Jochen Süss
Ticks and Tick-borne Diseases, 2011
M. Kwaśnik, J. Rola, W. Rożek
Journal of Clinical Medicine, 2023
Tibor Füzik, Petra Formanová, D. Růžek, et al.
Nature Communications, 2018
C. Voyiatzaki, Sevastiani Papailia, M. Venetikou, et al.
International Journal of Environmental Research and Public Health, 2022
Alberto Moraga-Fernández, C. Muñoz-Hernández, Marta Sánchez-Sánchez, et al.
Veterinary microbiology, 2023
Lisa Lucie Le Dortz, C. Rouxel, Bruno Polack, et al.
Veterinary parasitology, 2024
D. Růžek, Kristýna Kaucká
Ticks and tick-borne diseases, 2024
Peng C, Hao Y, Yuan Y, et al.
2025
- Phlebovirus
- Severe Fever with Thrombocytopenia Syndrome
- Arachnid Vectors
Bandavirus dabieense (commonly known as severe fever with thrombocytopenia syndrome virus, SFTSV) infection leads to severe fever with thrombocytopenia syndrome (SFTS), which is an emerging tick-borne natural focus disease discovered in middle-eastern China. SFTS is characterized by fever with thrombocytopenia, and patients' main clinical manifestations are leucopenia, elevated serum liver enzymes, and multiple organ failure. Ticks are considered as carriers of SFTSV transmission, and Haemaphysalis longicornalis is considered the main vector tick. SFTSV is disseminated through the migration or movement of tick-carrying migratory birds and other animal hosts. With changes in climate and environment, the habitat of ticks such as haemaphysalis longicornalis are continuously expanding, coupled with the diverse animal host species of the ticks. SFTS is evolving into a serious global public safety issue. In the absence of specific treatments and vaccines still being developed, monitoring and vector control are crucial for curbing the spread of SFTSV. Here, based on the existing literature, we reviewed the epidemiology, infection mechanism, clinical characteristics, diagnosis, prevention and clinical treatment of SFTSV to enhance the understanding of the SFTSV, with the aim of providing a theoretical basis guidance for the government and relevant institutions to prevent and control the further spread of SFTSV.
Abstract licence: CC BY
K. Blom, Angélica Cuapio, J. Sandberg, et al.
Frontiers in Immunology, 2018
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.